Could Revolution Medicines (RVMD) Become a $20 Billion Cancer Drug Story?

In its second-quarter 2026 capitalist letter, Baron Health Care Fund highlighted Revolution Medicines, Inc. (NASDAQ:RVMD) arsenic a caller addition. Revolution Medicines, Inc. (NASDAQ:RVMD) is simply a clinical-stage precision oncology institution that develops caller targeted therapies for RAS-addicted cancers. On August 3, 2026, Revolution Medicines, Inc. (NASDAQ:RVMD) closed astatine $182.45 per share. The one-month instrumentality of Revolution Medicines, Inc. (NASDAQ:RVMD) was -4.21% and its shares gained 375.25% implicit the past 52 weeks. Revolution Medicines, Inc. (NASDAQ:RVMD) has a marketplace capitalization of $38.79 billion.

Baron Health Care Fund stated the pursuing regarding Revolution Medicines, Inc. (NASDAQ:RVMD) in its Q2 2026 capitalist letter:

"We added to our presumption in Revolution Medicines, Inc., a biotechnology institution processing medicines to dainty cancers driven by rat sarcoma (RAS) mutations. The institution estimates determination are 190,000 caller crab diagnoses each twelvemonth successful the U.S. that are driven by RAS mutations, including astir 60,000 patients with non-small compartment lung cancer, 75,000 patients with colorectal cancer, and 56,000 patients with pancreatic cancer. In April, the institution released topline results from its RASolute 302 proceedings successful which patients with precocious pancreatic crab who received the company's medicine Daraxonrasib in the 2nd enactment had a median wide endurance of 13.2 months compared to 6.7 months for the patients who received chemotherapy. Subsequently astatine the yearly gathering of the American Society of Clinical Oncology (ASCO), the objective proceedings investigators presented the afloat information which confirmed the groundbreaking results. In this diligent population, Daraxonrasib reduced the hazard of decease by 60% compared with chemotherapy. The presumption astatine ASCO received a lasting ovation, which is uncommon successful oncology and adjacent rarer successful pancreatic cancer. Daraxonrasib represents the archetypal large beforehand successful pancreatic crab successful implicit 30 years. Also, during the quarter, the institution announced encouraging information from 2 earlier signifier trials of Daraxonrasib in first-line (previously untreated) pancreatic crab patients. The company is besides studying Daraxonrasib in non-small compartment lung crab and different solid tumors and has different drugs successful development, including operation therapies, for each of these cancers. When Daraxonrasib is FDA approved aboriginal this year, we deliberation the request volition beryllium strong, starring to accelerated adoption. We deliberation the company's enactment presumption successful this class volition beryllium hard to displace, and ultimately, we deliberation the institution could make highest income implicit $20 billion."